

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
30 January 2025 (30.01.2025)



(10) International Publication Number
WO 2025/022285 A2

(51) International Patent Classification:
A61K 51/04 (2006.01) *A61P 35/00* (2006.01)

(21) International Application Number:
PCT/IB2024/057048

(22) International Filing Date:
19 July 2024 (19.07.2024)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
63/514,849 21 July 2023 (21.07.2023) US

(71) Applicant: **NOVARTIS AG** [CH/CH]; Lichtstrasse 35,
4056 Basel (CH).

(72) Inventors: **CASTALDI, Elena**; c/o Advanced Accelerator
Applications (Italy) - S.R.L., Via dell'industria Prima Tra-
versa, 86077 Pozzilli (IT). **DALAL, Darshan**; 144 E 36th
Street, Apt. 7C, New York, New York 10016 (US). **FOR-**
MENTO CAVAIER, Roberto; c/o Advanced Accelerator
Applications (Italy) - S.R.L., Via dell'industria Prima Tra-
versa, 86077 Pozzilli (IT). **MAINERO, Valentina**; c/o Ad-
vanced Accelerator Applications (Italy) - S.R.L., Via del-
l'industria Prima Traversa, 86077 Pozzilli (IT). **MARIANI,**
Maurizio Franco; c/o Advanced Accelerator Applications
(Italy) - S.R.L., Via dell'industria Prima Traversa, 86077
Pozzilli (IT). **MESSMANN, Richard**; 3000 Kent Avenue,
West Lafayette, Indiana 47906 (US). **MOOKERJEE, Bi-**
joyesh Prasanna; c/o Novartis Pharmaceuticals Corpora-
tion, 59 Route 10, East Hanover, New Jersey 07936 (US).
OLIVEIRA PORTELLA, Maria do Socorro; 32 Pud-
dingstone Way, Florham Park, New Jersey 07932 (US).
WILKE, Celine Christiana Anna; c/o Novartis Pharma
AG, Lichtstrasse 35, 4056 Basel (CH). **ZAHl, Ilyes**; 20 av-
enue de la Coquetterie, 44000 Nantes (FR).

(81) Designated States (*unless otherwise indicated, for every
kind of national protection available*): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG,
KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY,
MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every
kind of regional protection available*): ARIPO (BW, CV,
GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST,
SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ,
RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ,
DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT,
LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,
SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- *without international search report and to be republished
upon receipt of that report (Rule 48.2(g))*
- *in black and white; the international application as filed
contained color or greyscale and is available for download
from PATENTSCOPE*

(54) Title: PSMA-TARGETING RADIOLIGAND TREATMENT REGIMEN

(57) Abstract: Described herein are radiopharmaceuticals for the treatment of PSMA-expressing cancers, as well as methods and/or
uses of such compounds for treating PSMA-expressing cancers, such as, e.g., metastatic castration resistant prostate cancers.



WO 2025/022285 A2